Esperion Therapeutics (ESPR) Tops Q3 EPS by 18c; Reports Cash and Cash Equivalents of $153.7M

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.62), $0.18 better than the analyst estimate of ($2.80). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $12.85 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Fort Technology posts 49% revenue rise in first half of 2026
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15